All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

A global education and awareness initiative that provides patients and caregivers with information and resources to support them on their journey with graft-versus-host disease.

Visit Know GvHD

Join us in supporting GvHD Day on February 17

  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOG IN
You're logged in! Click here any time to manage your account or log out.
LOG IN
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2018-03-26T12:24:36.000Z

Dr. Frederic Baron | EBMT 2018 | The role of azacitidine in GvHD prevention

By Frederic Baron
Mar 26, 2018
Share:

Bookmark this article

Dr. Frederic Baron discusses the role of azacitidine in GvHD prevention at EBMT 18

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

Thank you for rating this video.

The content addressed the learning objectives

Thank you for rating this video.

The content was relevant to my practice

Thank you for rating this video.

The role of azacitidine in GvHD prevention

More about...
AzacitidineEBMT 2018

Your opinion matters

HCPs, what is your preferred format for educational content on the GvHD Hub?
16 votes - 58 days left ...

Related articles

Add bookmark

ASH 2022 abstracts: What’s hot in GvHD?

To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub Steering Committee members provided their recommendations for the top...

Dec 1, 2022
Add bookmark

ASH 2022 abstracts: What’s hot in GvHD?

To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub Steering Committee...

Dec 1, 2022
Add bookmark

EBMT 2018 | A new endpoint that accurately recognizes the long-term outcomes of allo-HCT in refractory GvHD

This study aimed to identify a new endpoint that accurately recognizes the long-term outcomes of allo-HCT including life expectancy, disease...

Mar 22, 2018
Add bookmark

EBMT 2018 | A new endpoint that accurately recognizes the long-term outcomes of allo-HCT in refractory GvHD

This study aimed to identify a new endpoint that accurately recognizes the long-term...

Mar 22, 2018

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox